You are here

  • Home
  • Archive
  • Volume 10, Issue Suppl 2
  • 1132 Impact of intralesional oncolytic viral therapy targeting in situ activation of CD40 and type 1 interferon signaling pathways on the TME and systemic T cell immunity in murine models and cancer patients

Citation Tools

Article menu

Download PDFPDF

Regular and Young Investigator Award Abstracts
Immune-Stimulants and Immune Modulators
1132 Impact of intralesional oncolytic viral therapy targeting in situ activation of CD40 and type 1 interferon signaling pathways on the TME and systemic T cell immunity in murine models and cancer patients
Free

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Saltos A, Zheng H, Arrowood C, et al
1132 Impact of intralesional oncolytic viral therapy targeting in situ activation of CD40 and type 1 interferon signaling pathways on the TME and systemic T cell immunity in murine models and cancer patients
Journal for ImmunoTherapy of Cancer 2022;10:doi: 10.1136/jitc-2022-SITC2022.1132